MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
6.40
-0.07
-1.08%
After Hours: 6.26 -0.14 -2.19% 19:57 03/24 EDT
OPEN
6.33
PREV CLOSE
6.47
HIGH
6.52
LOW
6.22
VOLUME
1.17M
TURNOVER
--
52 WEEK HIGH
7.39
52 WEEK LOW
2.300
MARKET CAP
618.77M
P/E (TTM)
-13.6228
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TRVI last week (0317-0321)?
Weekly Report · 16h ago
Trevi Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges
TipRanks · 3d ago
Trevi Therapeutics Price Target Raised to $20.00/Share From $11.00 by B. Riley Securities
Dow Jones · 5d ago
B. Riley Securities Reiterates Buy on Trevi Therapeutics, Raises Price Target to $20
Benzinga · 5d ago
Trevi Therapeutics Is Maintained at Buy by Needham
Dow Jones · 5d ago
Trevi Therapeutics Price Target Cut to $24.00/Share From $25.00 by Needham
Dow Jones · 5d ago
Trevi Therapeutics Price Target Maintained With a $21.00/Share by D. Boral Capital
Dow Jones · 5d ago
Trevi Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 5d ago
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.